



Immunotherapy for Metastatic Kidney Cancer Shows Increased Survival



The immune checkpoint inhibitor Opdivo (nivolumab) has been shown to increase survival for patients with metastatic clear cell kidney cancer (also called renal cell carcinoma, or RCC).

[Download Transcript](#)

Please feel free to offer comments and raise questions in our [Discussion Forums](#).